Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC
Patients with metastatic colorectal cancer (mCRC) and quadruple wild-type genes showed significant benefit from continuing anti-EGFR therapy beyond progression. Second-line cetuximab plus FOLFOX chemotherapy improved progression-free survival, response rate, and overall survival in patients without genetic mutations.